ReviewJournal of fungi (Basel, Switzerland)2021
When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis.
Review in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 236 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
236 citing papers in PubMed, 3 syntheses or guidelines pooled it, 521 citations in OpenAlex.
- A systematic review on SARS-CoV-2-associated fungal coinfections.Journal of medical virology · 2022Pooled it
- Pooled it
- A Review of Prolonged Post-COVID-19 Symptoms and Their Implications on Dental Management.International journal of environmental research and public health · 2021Pooled it
- Explainable deep learning techniques for microscopic fungi classification using a learnable threshold-based ReLULeaky activation function and transfer learning.Journal of pathology informatics · 2026Article
- Rhino-Orbital Mucormycosis Following COVID-19 Viral Vector Vaccination in an Immunocompetent Patient.Journal of fungi (Basel, Switzerland) · 2026Article
- Risk factors for mucormycosis among diabetic individuals, Bathinda, Punjab: a case-control study.BMC infectious diseases · 2026Article
- Review
- Clinical profile and outcome of COVID-19 associated mucormycosis in Shiraz, South Iran: a longitudinal study.Iranian journal of microbiology · 2026Article
- Mapping Mucormycosis Research: A 25-Year Bibliometric Analysis of Medical Literature.Infectious diseases & clinical microbiology · 2026Article
- Risk Factors and Clinical Outcomes of Invasive Fungal Infections in Patients with Severe COVID-19: A Case-Control Study.Pathogens (Basel, Switzerland) · 2025Article
- Post-COVID-19 Maxillary Bony Sequestration: A Case Report on Mucormycosis Challenges.Clinical case reports · 2025Article
- Article
- Article
- Commemorating the Landmark Advances in Our Understanding of Mucormycosis by Dimitrios P. Kontoyiannis.Journal of fungi (Basel, Switzerland) · 2025Article
- Enhancing clinical and histopathological insights on COVID-19-associated mucormycosis (CAM).Journal of family medicine and primary care · 2025Article
- Co-Infection of Mucormycosis and COVID-19: A Retrospective Cross-Sectional Study of Patients Admitted to Imam Khomeini Hospital in Ahvaz, Iran.Health science reports · 2025Article
- Increased serum ferritin is associated with severity of orbital disease in COVID-19-associated rhino-orbito-cerebral mucormycosis: A quantitative analysis.Indian journal of ophthalmology · 2025Article
- COVID-19-Associated Mucormycosis Mimicking Odontogenic Pain: A Report of Three Cases.Case reports in dentistry · 2025Article
- Evaluation of the Imaging Characteristics of Rhino-Orbital Cerebral Mucormycosis.World journal of plastic surgery · 2025Article
- Clinical Challenges and Predictive Risk Factors for Outcomes in COVID-19-Associated Mucormycosis.Iranian journal of pathology · 2025Article
176 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis (MCR) has been increasingly described in patients with coronavirus disease 2019 (COVID-19) but the epidemiological factors, presentation, diagnostic certainty, and outcome of such patients are not well described. We review the published COVID-19-associated mucormycosis (CAMCR) cases (total 41) to identify risk factors, clinical features, and outcomes. CAMCR was typically seen in patients with diabetes mellitus (DM) (94%) especially the ones with poorly controlled DM (67%) and severe or critical COVID-19 (95%). Its presentation was typical of MCR seen in diabetic patients (mostly rhino-orbital and rhino-orbital-cerebral presentation). In sharp contrast to reported COVID-associated aspergillosis (CAPA) cases, nearly all CAMCR infections were proven (93%). Treating physicians should have a high suspicion for CAMCR in patients with uncontrolled diabetes mellitus and severe COVID-19 presenting with rhino-orbital or rhino-cerebral syndromes. CAMR is the convergence of two storms, one of DM and the other of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.